Back to top

messenger-rna: Archive

Sundeep Ganoria

Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?

MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.

MRNAPositive Net Change BNTXPositive Net Change PFEPositive Net Change MRKPositive Net Change

Sundeep Ganoria

MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going

Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.

MRNAPositive Net Change SNYNegative Net Change PFEPositive Net Change MRKPositive Net Change